These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21425143)

  • 1. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
    Alicikus ZA; Yamada Y; Zhang Z; Pei X; Hunt M; Kollmeier M; Cox B; Zelefsky MJ
    Cancer; 2011 Apr; 117(7):1429-37. PubMed ID: 21425143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
    Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
    J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benefit of intensity modulated and image-guided radiotherapy in prostate cancer].
    Latorzeff I; Mazurier J; Boutry C; Dudouet P; Richaud P; de Crevoisier R
    Cancer Radiother; 2010 Oct; 14(6-7):479-87. PubMed ID: 20797889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy.
    Namiki S; Ishidoya S; Tochigi T; Kawamura S; Kuwahara M; Terai A; Yoshimura K; Numata I; Satoh M; Saito S; Takai Y; Yamada S; Arai Y
    Jpn J Clin Oncol; 2006 Apr; 36(4):224-30. PubMed ID: 16537689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer.
    Ost P; De Troyer B; Fonteyne V; Oosterlinck W; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1316-22. PubMed ID: 20675081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.
    Deutsch I; Zelefsky MJ; Zhang Z; Mo Q; Zaider M; Cohen G; Cahlon O; Yamada Y
    Brachytherapy; 2010; 9(4):313-8. PubMed ID: 20685176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
    Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin JK; Lizarde J; Macedo JC; Ravera J; Tokita KM
    Brachytherapy; 2010; 9(4):341-8. PubMed ID: 19853534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer.
    Namiki S; Ishidoya S; Ito A; Tochigi T; Numata I; Narazaki K; Yamada S; Takai Y; Arai Y
    Jpn J Clin Oncol; 2009 Nov; 39(11):732-8. PubMed ID: 19666904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.